Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B

Table 1 Percent reduction in parasite burden by KALSOME™ 10, AmB and AmBisome therapy, estimated by LDA

Drug		Percent reduction in LDA values
Drug		Liver	Spleen
3.5 mg/kg SD*	KALSOME™10	53.02	55.7
7.5 mg/kg SD	KALSOME™10	78.1	77.02
7.5 mg/kg DD	KALSOME™10	100	94.6
2.5 mg/kg	AmB	40.65	57.39
3.5 mg/kg	AmBisome	54.78	72.02

Groups of 3–6 infected BALB/c mice were treated with the various doses of the drugs (KALSOME™10, AmB and AmBisome). After one month, mice were sacrificed to estimate the parasite burden as described in Methods. Percent reduction in LDA of liver and spleen was calculated based on that of infected control. *SD: single Dose; ^¶DD: Double Dose.

ISSN: 1471-2334